Use of oxymetazoline hydrochloride ophthalmic solution, 0.1% for improved lid symmetry in Graves' disease.

Autor:	Vogt AZ; Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, USA., Vrcek IM; Ophthalmology, Texas Ophthalmic Plastic, Reconstructive & Orbital Surgery Associates, Dallas, Texas, USA.
Jazyk:	angličtina
Zdroj:	Orbit (Amsterdam, Netherlands) [Orbit] 2024 Aug 19, pp. 1-5. Date of Electronic Publication: 2024 Aug 19.
DOI:	10.1080/01676830.2024.2389303
Abstrakt:	Purpose: The purpose of this study is to evaluate the usage of oxymetazoline hydrochloride ophthalmic solution, 0.1% in the treatment of Graves' disease to improve lid symmetry. Methods: Fourteen patients were identified with unilateral upper eyelid retraction, secondary to Graves' disease. A phenylephrine test was performed to evaluate whether treating the unaffected (non-retracted) side would result in improved symmetry using Hering's law. Patients were prescribed oxymetazoline hydrochloride ophthalmic solution, 0.1% to instill into the unaffected eye. Marginal reflex distance 1 (MRD1) measurements were taken pre- and post-treatment and patient satisfaction surveys were completed. Results: The average pre-treatment MRD1 difference between the right eye (OD) and the left eye (OS) was 2.46 [range 1.50-4.00]. The average post-treatment MRD1 difference between OD and OS was 0.39 [range 0.00-1.00]. One hundred percent of patients were satisfied or very satisfied with the improvement in symmetry. Conclusions: Oxymetazoline hydrochloride ophthalmic solution, 0.1% is a potential method to improve symmetry in patients with Graves' disease and unilateral upper eyelid retraction via Hering's law, especially for non-surgical candidates or those who prefer non-surgical treatment. Our results indicate improved MRD1 differences between fellow eyes and patient satisfaction regarding the symmetry of the upper eyelids.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu